Department News
Neoplastic Diseases and Related Disorders Clinical Trials
Active Clinical Trials: Neoplastic Diseases and Related Disorders
Colon Cancer:
1. A Randomized Phase III Trial of Irinotecan 9CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer. P.I. Paul Ritch, MD Study Coordinator: Lorna Rogahn, 805-4196 Pager: 318-3152
2. A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin, and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers. P.I. Nicholas Choong, MD Study Coordinator: Lorna Rogahn, 805-4196 Pager: 318-3152
3. A Randomized, Placebo-Controlled Phage II Study of GDC-0449 (HEDGEHOG Antagonist) with Concurrent Chemotherapy and Bevacizumab as First-Line Therapy for Metastatic Colorectal Cancer. P.I. Paul Ritch, MD Study Coordinator: Lorna Rogahn, 805-4196 Pager: 318-3152, Study Coordinator: Katie Worzalla, 805-8972 Pager: 318-5772
4. Use of the Comprehensive Geriatric Assessment in Older Colorectal Cancer Patients to Identify Vulnerability and Guide Treatment Choices. P.I. Kathryn Bylow, MD Study Coordinator: Lorna Rogahn, 805-4196 Pager: 318-3152
Esophageal Cancer:
5. A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer who are Treated without Surgery. P.I. Elizabeth Gore, MD Study Coordinator: Joyce Olson, RN, 805-4375
Gastroesophageal Cancer:
6. Phase III Intergroup of Adjuvant chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma. P.I. Beth Erickson, MD Study Coordinator: Joyce Olson, RN, 805-4375
Gastric & Gastroesophageal Junction Cancer:
7. A Random Assignment Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) versus Parent DCF with Growth Factor Support in Patients with Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma. P.I. Paul Ritch, MD Study Coordinator: Brenda Davies, 805-4639 Pager: 318-0955
Gastrointestinal Stromal Cancer:
8. A Phase II Study of BAY 43-9006 for Patients with Imatinib-Resistant Malignant Gastrointestinal Stromal Tumor. P.I. Stuart Wong, MD Study Coordinator: Lorna Rogahn, 805-4196 Pager: 318-3152
Liver Cancer:
9. A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally at a Dose of 800 mg Daily or Doxorubicin Administered Intravenously at a Dose of 60 mg/m2 Every 3 weeks in Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma. P.I. Paul Ritch, MD Study Coordinator: Brenda Davies, 805-4639 Pager: 318-0955
Pancreatic Cancer:
10. A Randomized, Phase II/III Study of TNFerade Biologic with 5-FU and Radiation Therapy for first-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer. (GV-001.004). P.I. Paul Ritch, MD Study Coordinator: Brenda Davies, 805-4639 Pager: 318-0955
11. Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combine with a Gemcitabine Regimen v. a Gemcitabine Regimen with Placebo, in Patients with Post-Resection Ro/R1 Pancreatic Cancer. P.I. Paul Ritch, MD Study Coordinator: Kathy Brown, RN, 805-6834 Pager: 318-0115
12. A Randomized, Double-Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First Line Treatment to Subjects with Unrespectable, Locally Advanced, or Metastatic Pancreatic Adenocarcinoma. P.I. Paul Ritch, MD Study Coordinator: Kathy Brown, RN, 805-6834 Pager: 318-0115
Rectal Cancer:
13. Phase II Study of Preoperative Radiation with Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLOFOX) and Bevacizumab in Patients with Locally Advanced Rectal Cancer. P.I. Paul Ritch, MD Study Coordinator: Lorna Rogahn, 805-4196 Pager: 318-3152
14. Intensity Modulated Radiation therapy (IMRT) in Combination with Capecitabine and Oxaliplatin for Patients with Locally Advanced Rectal Cancer. P.I. Beth Erickson, MD Study Coordinator: Anna Koziel, RN, 805-0261